This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. Its mechanisms may include: 1. Increasing the sensitivity of peripheral tissues to insulin and increasing insulin-mediated glucose utilization; 2. Increasing the utilization of glucose by non-insulin-dependent tissues; 3. Inhibiting hepatic gluconeogenesis and reducing hepatic glucose output; 4. Inhibiting intestinal wall cells from taking up glucose; 5. Inhibiting the biosynthesis and storage of cholesterol and reducing blood triglyceride and total cholesterol levels. This product has no effect on promoting fat synthesis, no obvious hypoglycemic effect on normal people, and has a significant therapeutic effect on type 2 diabetes.

This product is a protease activator that activates protein decomposition. After eye drops, it can penetrate into the lens, decompose and absorb denatured proteins, maintain lens transparency, improve eye tissue metabolism, and prevent the progression of cataracts.

It has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone, showing obvious corticosteroid-like effects, such as anti-inflammatory, anti-allergic and protective membrane structure; promoting monochromatic metabolism, reducing the release of ALT and AST; inducing γ-IFN and interleukin II, increasing NK cell activity and OKT4/OKT8 ratio and activating the reticuloendothelial system; inhibiting the release of histamine from mast cells; inhibiting the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reactions; inhibiting the production and formation of free radicals and lipid peroxides, reducing the activity of proline hydroxylase; regulating calcium ion channels, protecting lysosomal membranes and mitochondria

No specific pharmacological action is mentioned

No specific pharmacological action is mentioned

Antiviral drug. It has the effect of inhibiting the growth of many viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.